PDF factsheet
      Z

HR-slowing agents in stable angina for all type of patients, clinical trials results

ivabradine versus amlodipine
CL3-023 (15mg), 0
ivabradine 7.5mg twice daily
versus
amlodipine
double-blind
Follow-up duration: 3 months
CL3-023 (20mg), 0
ivabradine 10mg twice daily
versus
amlodipine
double-blind
Follow-up duration: 3 months
ivabradine 10mg versus placebo
Borer (CL2-009) 10mg, 2003
Ivabradine 5 mg twice daily (10mg/d)
versus
placebo
double blind
Follow-up duration: 2 weeks
ivabradine 10mg versus placebo on top of amlodipine
CL3-018 10mg, 3000
ivabradine 5mg twice daily (10mg/d)
versus
placebo

Follow-up duration: 12 weeks
ivabradine 15mg versus amlodipine
Ruzyllo (CL3-023) 15mg, 2007
ivabradine 7.5mg twice daily
versus
amlodipine 10mg once daily
Patients with a >/=3-month history of chronic, stable effort-induced angina double-blind
Follow-up duration: 3 months
ivabradine 15mg versus atenolol
INITIATIVE (CL3-017, Tardif) 15mg, 2005
ivabradine 5 mg bid for 4 weeks and then either 7.5 or 10 mg bid for 12 weeks
versus
atenolol 50 mg od for 4 weeks and then 100 mg od for 12 weeks
patients with stable angina double-blind
Follow-up duration: 16 weeks
ivabradine 15mg versus placebo (on top standard treatment)
BEAUTIFUL (angina subgroup),
ivabradine target dose of 7ยท5 mg twice a day
versus
placebo
patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina double blind
Follow-up duration: 19 months (range 16-24)
33 countries
ivabradine 15mg versus placebo on top of amlodipine
CL3-018 15mg, 3000
ivabradine 7.5mg twice daily (15mg/d)
versus
placebo
ivabradine 15mg versus placebo on top of atenolol
ASSOCIATE (Tardif), 2009
NCT00202566
ivabradine 5 mg b.i.d. for 2 months, increased to 7.5 mg b.i.d. for a further 2 months (on top atenolol 50 mg/day )
versus
placebo on top atenolol 50 mg/day
patients with stable angina receiving atenolol 50 mg/day or another beta-blocker at equivalent doses for at least 3 months double blind
Follow-up duration: 4 months
20 countries
ivabradine 20mg versus amlodipine
Ruzyllo (CL3-023) 20mg, 2007
ivabradine 10mg twice daily
versus
amlodipine 10mg once daily
Patients with a >/=3-month history of chronic, stable effort-induced angina double-blind
Follow-up duration: 3 months
ivabradine 20mg versus atenolol
INITIATIVE (CL3-017, Tardif) 20mg, 2005
ivabradine 5 mg bid for 4 weeks and then 10 mg bid for 12 weeks
versus
atenolol 50 mg od for 4 weeks and then 100 mg od for 12 weeks
patients with stable angina double-blind
Follow-up duration: 16 weeks
ivabradine 20mg versus placebo
SIGNIFY, 2014
ISRCTN61576291
ivabradine, at a dose of up to 10 mg twice daily, with the dose adjusted to achieve a target heart rate of 55 to 60 beats per minute.
versus
placebo
patients who had both stable coronary artery disease without clinical heart failure and a heart rate of 70 beats per minute or moredouble-blind
Follow-up duration: 27.8 mo (median)
Borer (CL2-009) 20mg, 2003
ivabradine 10mg twice daily (20mg/d)
versus
placebo
double blind
Follow-up duration: 2 weeks
ivabradine 5mg versus placebo
Borer (CL2-009) 5mg, 2003

versus
double blind
Follow-up duration: 2 weeks

  Options


in first

in second

  Filter